IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0720306
(2010-03-09)
|
등록번호 |
US-8208984
(2012-06-26)
|
발명자
/ 주소 |
- Blomquist, Michael
- Pope, Rhall E.
|
출원인 / 주소 |
|
대리인 / 주소 |
Patterson Thuente Christensen Pedersen, P.A.
|
인용정보 |
피인용 횟수 :
14 인용 특허 :
67 |
초록
▼
An apparatus comprises receiving a user prompt in a blood glucose (BG) management device to start a determination of an effective correction factor, receiving sampled blood glucose data of a patient obtained during a specified time duration, including a time duration after delivery of an initial ins
An apparatus comprises receiving a user prompt in a blood glucose (BG) management device to start a determination of an effective correction factor, receiving sampled blood glucose data of a patient obtained during a specified time duration, including a time duration after delivery of an initial insulin correction bolus, determining the effective correction factor using the BG management device according to a determined decrease in the blood glucose level of the patient and an amount of insulin in the initial insulin correction bolus, and cancelling the determination of the effective correction factor if a blood glucose level of the patient is outside of a specified range of blood glucose levels.
대표청구항
▼
1. A method comprising: receiving a user prompt in a blood glucose (BG) management device to start a determination of an effective correction factor;receiving sampled blood glucose data of a patient obtained during a specified time duration, including a time duration after delivery of an initial ins
1. A method comprising: receiving a user prompt in a blood glucose (BG) management device to start a determination of an effective correction factor;receiving sampled blood glucose data of a patient obtained during a specified time duration, including a time duration after delivery of an initial insulin correction bolus;determining the effective correction factor using the BG management device according to a determined decrease in the blood glucose level of the patient and an amount of insulin in the initial insulin correction bolus; andcancelling the determination of the effective correction factor if a blood glucose level of the patient is outside of a specified range of blood glucose levels. 2. The method of claim 1, further including delivering the initial insulin correction bolus to the patient using the BG management device or a second device, wherein the initial insulin correction bolus has an amount of insulin estimated, using a pre-bolus correction factor, to decrease a blood glucose level of the patient to within a first specified percentage of a target blood glucose baseline. 3. The method of claim 2, further including determining a second insulin correction bolus having an amount of insulin estimated, using the effective correction factor, to decrease a blood glucose level of the patient to within a second specified percentage of the target blood glucose baseline. 4. The method of claim 2, further including determining an amount of insulin in the initial insulin correction bolus using a rate of change of the blood glucose level of the patient. 5. The method of claim 2, further including determining an amount of carbohydrates for the patient to consume if the blood glucose level of the patient is below the target blood glucose level. 6. The method of claim 5, further including determining the amount of carbohydrates using a rate of change of the blood glucose level of the patient. 7. The method of claim 2, further including canceling the delivery of the initial insulin correction bolus and the effective correction factor determination if a measured blood glucose level of the patient is outside of a specified range of blood glucose levels. 8. The method of claim 2, including delivering the initial insulin correction bolus using the BG management device. 9. The method of claim 8, further including: determining an amount of active insulin in the patient prior to delivering the initial insulin correction bolus; andcanceling the effective correction factor determination if an amount of active insulin is above a specified threshold active insulin amount. 10. The method of claim 8, further including: determining an amount of active insulin in the patient prior to delivering the initial insulin correction bolus; anddetermining the amount of insulin in the initial insulin correction bolus by factoring in the amount of active insulin if the amount of active insulin is above a specified threshold active insulin amount. 11. The method of claim 8, wherein receiving sampled blood glucose data includes automatically receiving the sampled blood glucose data from a blood glucose monitor included in the BG management device. 12. The method of claim 8, wherein receiving sampled blood glucose data includes: obtaining the sampled blood glucose data using a device separate from the BG management device; andreceiving the sampled blood glucose data into the BG management device from the separate device through a communication port. 13. The method of claim 12, wherein receiving sampled blood glucose data includes wirelessly receiving the sampled blood glucose data into the BG management device from the separate device through a wireless communication port. 14. The method of claim 12, wherein receiving sampled blood glucose data includes periodically prompting a user through a user interface of the BG management device to obtain blood glucose data using the separate device. 15. The method of claim 8, wherein receiving sampled blood glucose data includes receiving the sampled blood glucose data through a user interface of the BG management device configured for manual entry of blood glucose data. 16. The method of claim 15, wherein receiving sampled blood glucose data includes prompting a user to manually enter a blood glucose value during the determination of the effective correction factor. 17. The method of claim 2, including delivering the initial insulin correction bolus using the second device; wherein receiving sampled blood glucose data includes automatically receiving the sampled blood glucose data from a blood glucose monitor included in the BG management device; andwherein the method further includes receiving the information related to insulin delivery into the BG management device. 18. The method of claim 17, wherein receiving the information related to insulin delivery includes receiving the information related to insulin delivery from the second device through a communication port. 19. The method of claim 18, further including communicating the effective correction factor to the second device using the communication port. 20. The method of claim 17, wherein receiving the information related to insulin delivery includes receiving the information related to insulin delivery manually through a user interface on the BG management device. 21. The method of claim 17, further including displaying the effective correction factor. 22. The method of claim 1, including: providing information related to insulin delivery, including an amount of active insulin, if any, in the patient and the pre-bolus correction factor, to the BG management device using a second device;calculating an initial insulin correction bolus using the BG management device;delivering the initial insulin correction bolus using the second device;wherein at least one of the sampled blood glucose information and the information related to insulin delivery includes a time-stamp, andwherein determining the effective correction factor includes determining the effective correction factor using the sampled blood glucose data and the insulin delivery information.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.